Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 477-481, 2022.
Article
in Zh
| WPRIM
| ID: wpr-939734
Responsible library:
WPRO
ABSTRACT
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC.
.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Proto-Oncogene Proteins p21(ras)
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Proteolysis
/
Lung Neoplasms
/
Mutation
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Type:
Article